Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
10:00am, Wednesday, 20'th May 2026
Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo i
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
09:00am, Wednesday, 20'th May 2026
NEW YORK--(BUSINESS WIRE)--Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line m
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
03:30pm, Tuesday, 19'th May 2026
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
12:56pm, Tuesday, 19'th May 2026
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations
09:00am, Tuesday, 19'th May 2026
Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in.
Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%. NEW YORK, May 18, 2026 /PRN
Regeneron stock drops double digits on oncology trial failure
03:25pm, Monday, 18'th May 2026
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal lat
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky About Fraud Investigation
03:20pm, Monday, 18'th May 2026
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc."
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
03:17pm, Monday, 18'th May 2026
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today
01:07pm, Monday, 18'th May 2026
U.S. equities opened the new trading week on a split footing on Monday as a sharp unwind in AI-infrastructure names dragged the Nasdaq 100 down by over 1%, while energy, communications and insurance s
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
12:01pm, Monday, 18'th May 2026
Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma.
Stock Futures Climb as Investors Monitor Middle East
09:09am, Monday, 18'th May 2026
Stock futures are in the black, with the Dow cautiously higher as investors watch U.S. and Iran
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda
08:31am, Monday, 18'th May 2026
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has pro
Pre-Market Stock Futures: Futures are trading lower after a spectacular week came to an abrupt end Friday, as all the major indices were absolutely hammered. Voices across financial media were busy po
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
07:28am, Monday, 18'th May 2026
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
